BioWorld Asia

March 3, 2004

Oncology-Focused Igeneon Raises EUR26.7M, Ponders IPO

Igeneon AG raised €26.7 million in a third-round venture financing and landed Burrill & Co., of San Francisco, as a co-lead investor. (BioWorld International) Read More

Active Biotech Cuts Work Force; Focus Now On Current Portfolio

How Salmonella Coaxes Gut Cell To Give Warm Embrace

Monsanto GM Rapeseed Product Receives EU Scientific Clearance

Phytopharm Raises £6.5M, Plans Partnering Of Obesity Drug P57

NCI Begins Exploratory Cancer Trials With Xenova's Tariquidar

Start-Up Vaxon Seeking EUR7M For Novel Cancer Vaccines

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...